• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

    33.93 +0.03 (+0.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,156,298
    Open 34.12
    Bid (Size) 33.30 (300)
    Ask (Size) 35.53 (600)
    Prev. Close 33.90
    Today's Range 33.21 - 35.50
    52wk Range 15.60 - 36.88
    Shares Outstanding 79,199,501
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
    Are there significant gains ahead for one (or both) of these innovative biotechs? 
    Via The Motley Fool

    Performance

    YTD
    +25.0%
    +25.0%
    1 Month
    +13.9%
    +13.9%
    3 Month
    +46.8%
    +46.8%
    6 Month
    +20.6%
    +20.6%
    1 Year
    +97.8%
    +97.8%

    More News

    Read More
    News headline image
    Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗
    Via MarketBeat
    Topics Intellectual Property
    BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗
    Via Stocktwits
    News headline image
    Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
    Via MarketBeat
    Topics Intellectual Property
    News headline image
    Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors. ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
    Via MarketMinute
    Topics Intellectual Property Lawsuit
    News headline image
    Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    What's Going On With Beam Therapeutics Stock? ↗
    Via Benzinga
    News headline image
    Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    News headline image
    Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
    From Beam Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Beam Therapeutics Inc. - Common Stock publicly traded?
    Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Beam Therapeutics Inc. - Common Stock trade on?
    Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?
    The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market
    What is the current price of Beam Therapeutics Inc. - Common Stock?
    The current price of Beam Therapeutics Inc. - Common Stock is 33.93
    When was Beam Therapeutics Inc. - Common Stock last traded?
    The last trade of Beam Therapeutics Inc. - Common Stock was at 06/25/26 04:00 PM ET
    What is the market capitalization of Beam Therapeutics Inc. - Common Stock?
    The market capitalization of Beam Therapeutics Inc. - Common Stock is 2.69B
    How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?
    Beam Therapeutics Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.